Trial Profile
The effectiveness of everolimus (EVR) in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Methylprednisolone; Mycophenolate mofetil; Tacrolimus
- Indications Diabetes mellitus; Renal transplant rejection
- Focus Therapeutic Use
- 17 Apr 2018 New trial record
- 06 Apr 2018 Primary endpoint (Graft outcomes )has not been met, according to results published in the Transplantation Proceedings.
- 06 Apr 2018 Results published in the Transplantation Proceedings